Alerta De Seguridad para Trade name: DBS ELETRODE FOR DEEP BRAIN STIMULATION; DEEP BRAIN STIMULATION ELECTRODE; KIT CATETER DBS ELECTRODE FOR DEEP BRAIN STIMULATION Technical name: DBS ELETRODE FOR DEEP BRAIN STIMULATION; DEEP BRAIN STIMULATION ELECTRODE; KIT CATETER DBS ELECTRODE FOR DEEP BRAIN STIMULATION ANVISA registration number: 10339190484; 10339190549; 10339190339 Hazard Class: IV Affected Model: 3387S-40, 3389S-28, 3389S-40 and 3391S-40

Según Agência Nacional de Vigilância Sanitária (ANVISA), este evento ( alerta de seguridad ) involucró a un dispositivo médico en Brazil que fue producido por MEDTRONIC COMERCIAL LTDA; Medtronic Inc..

¿Qué es esto?

Las alertas proporcionan información importante y recomendaciones sobre los productos. Aunque se haya emitido una alerta, esto no significa necesariamente que el producto se considera peligroso. Las alertas de seguridad, dirigidas a trabajadores de la salud y a usuarios, pueden incluir retiro de equipos. Pueden ser escritas por los fabricantes, pero también por funcionarios del área de salud.

Más información acerca de la data acá
  • Tipo de evento
    Safety alert
  • ID del evento
    2231
  • Fecha
    2017-03-17
  • País del evento
  • Fuente del evento
    ANVISA
  • URL de la fuente del evento
  • Notas / Alertas
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • Notas adicionales en la data
    If your surgical procedure involves the use of Medtronic's DBS depth limiter, Medtronic recommends the following: • For the implanted product: If the product has already been implanted, no action is necessary once the electrode placement at the target site was confirmed by intraoperative test stimulus, imaging and / or efficacy of the therapy. • For the product to be implanted: If it is suspected that the depth limiter has not been properly attached to the electrode, do not use and complete the procedure using a depth limiter from another Medtronic DBS electrode kit. As stated in the DBS electrode implant manual, Medtronic recommends checking the effect of the stimulus during the implant procedure and using imaging techniques to confirm electrode placement. #### UPDATED ON 7/24/2017, Medtronic Company submitted the field action completion report verifying the submission of the safety notice.
  • Causa
    The medtronic dbs depth limiter, also referred to as electrode holder, is used to establish the depth of the implant. the depth limiter interacts with parts of the stereotactic system used during surgery to control the placement of the tip of the dbs electrode at the target site. this letter provides information regarding a product performance problem that has been identified in this component, potential patient risks, and actions to be taken in connection with the use of medtronic's depth limiter.
  • Acción
    Field Action Code FA761 triggered under the responsibility of the company MEDTRONIC COMERCIAL LTDA. Company will update, correct or supplement the instructions for use.

Manufacturer

  • Empresa matriz del fabricante (2017)
  • Comentario del fabricante
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    ANVSANVISA